Skip to main content
  • English
  • Français
  • About Us
    • About Us
    • Our Purpose and Identity
    • Integrated Report 2021
    • Governance
      • Governance
      • Board of Directors
      • Executive Committee
    • Where we are
    • Through time
    • All Our Stories
      • All Our Stories
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
  • Your Health
    • Your Health
    • Health and Well-Being
    • Diabetes and Cardiovascular Diseases
    • Specialty Care
      • Specialty Care
      • Rare Diseases
      • Rare Blood Disorders
      • Neurology
      • Immunology
      • Oncology
        • Oncology
        • When Cancer Grows Old
          • When Cancer Grows Old
          • Contributions Initiative
          • Global collaboration
      • Patient Support
    • Vaccines
      • Vaccines
      • The Value of vaccines
      • How immunization works
      • Infectious Disease and Vaccines
        • Infectious Disease and Vaccines
        • COVID-19
        • Influenza
        • Meningococcal Meningitis
        • Pertussis
        • Poliomyelitis
        • Respiratory Syncytial Virus
        • Discover more
        • Research and Innovation
      • Vaccines Production
      • Vaccines Stories
    • Taking Medicines Safely
    • Patient Safety at Sanofi
  • Science & Innovation
    • Science & Innovation
    • Partnering
      • Partnering
      • Let's partner
      • Areas of Interest
        • Areas of Interest
        • China & Emerging Markets
        • Digital
        • General Medicines
        • Immunology
        • Neuroscience
        • Oncology
        • Out-Licensing
        • Rare Diseases
        • Technology Platforms
        • Vaccines
      • Meet the team
    • Research & Development
      • Research & Development
      • Sanofi Pipeline
      • Vaccines
      • Immunology and Inflammation
      • Neurology
      • Oncology
      • Pioneering Technology Platforms
        • Pioneering Technology Platforms
        • Genomic Medicine Technology Platform
        • mRNA Technology: Vaccines and Beyond
        • NANOBODY® Technology Platform
        • SYNTHORIN™ Technology Platform
      • Rare Blood Disorders R&D
      • Rare Diseases
      • Voices from the Lab
    • Clinical Trials & Results
      • Clinical Trials & Results
      • Phases
      • Our disclosure commitments
        • Our disclosure commitments
        • Sanofi Pharma
        • Sanofi Genzyme
        • Sanofi Pasteur
      • Our data sharing commitments
      • Managed Access Programs (MAPs)
      • Investigator Sponsored Studies and Externally Sponsored Collaboration
    • Collaboration & Awards
      • Collaboration & Awards
      • Europe
        • Europe
        • iAwards
        • iDEA-iTECH
      • North America
        • North America
        • iAwards
        • iDEA-iTECH
      • China
    • Science Stories
  • Our Responsibility
    • Our Responsibility
    • Access to Quality Healthcare – Sanofi Global Health
    • Environmental sustainability
    • Diversity, Equity and Inclusion
      • Diversity, Equity and Inclusion
      • Making an Impact
      • A Million Conversations
      • Global Poll
      • Board & Employee Groups
      • Gender Balance
        • Gender Balance
        • Women@Sanofi
      • Our Partners
      • Our LGBTQ+ Voice
      • Allyship
    • Healthcare for all
      • Healthcare for all
      • Humanitarian Aid Programs
      • Contributing to the eradication, elimination and control of some infectious diseases
      • Fighting Against Falsified Medicine
      • Serving the needs of patients with non-communicable diseases
    • Corporate Citizenship
    • Foundation S (Endowment Fund)
    • Ethics & Transparency
      • Ethics & Transparency
      • Patient Safety at Sanofi
      • Our Code of Conduct
    • Suppliers
    • Document center
      • Document center
      • All factsheets
      • Access to Healthcare and Pricing
      • Country reports and other documents
      • CSR Strategy and Value Creation
      • Duty of Vigilance incl. Supply Chain
      • Environment
      • Responsible Business
      • Governance, Controls and Procedures
      • Reporting Frameworks and Indicators
      • Social incl. Communities
  • |
  • Careers
    • Careers
    • Explore our career opportunities
    • A range of possibilities
      • A range of possibilities
      • Market access
      • Marketing
      • Medical
      • Production
      • Research & Development
      • Consumer Healthcare
      • Vaccines careers
      • Student / Graduate / Young Professionals
      • Discover more possibilities
    • Grow with us
      • Grow with us
      • Diversity & Inclusion
      • Development opportunity: how Sanofi empowers you
      • Benefits
  • Investors
    • Investors
    • Financial Calendar & Events
      • Financial Calendar & Events
      • Quarterly earnings at a glance
      • Investor presentations
      • Annual General Meetings
      • Broker conferences
    • Environmental, Social, Governance
      • Environmental, Social, Governance
      • Our Latest news
      • Our Double Materiality Assessment
      • ESG Newsletters
    • Corporate governance
      • Corporate governance
      • Governance
      • Board of Directors
      • Executive Committee
      • Specialist committee
      • Compensations
      • Standards & rules
      • Regulated agreements
      • Internal Control
    • Sanofi share and ADRs
      • Sanofi share and ADRs
      • Sanofi stock chart
      • Shareholding calculator
      • Dividends
      • ADRs
      • Shareholding structure
      • Vara consensus
      • Shares & voting rights
      • Share repurchases
    • Reports and publications
      • Reports and publications
      • Financial and CSR reports
      • Shareholder publications
    • Individual Shareholders
      • Individual Shareholders
      • Welcome to Sanofi
      • Being a shareholder
        • Being a shareholder
        • Five reasons to be a Sanofi shareholder
        • How to buy Sanofi shares
        • Registered shares
      • Shareholder events
        • Shareholder events
        • Financial Calendar
        • Annual General Meetings
        • Participate in General Meetings
      • Reports and publications
        • Reports and publications
        • Financial and CSR reports
        • Shareholder publications
      • Shareholders committee
    • Regulated information
    • Fixed Income
    • Contacts
  • Media
    • Media
    • Press releases
      • Press releases
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
    • Articles
      • Articles
      • 2019
    • Contacts
    • Media Alert
  • |
  • Paris 2024 Partnership
Worldwide
EN
  • EN
  • FR

MEDIA

Press Releases 2019

  • Home
  • Media
  • Press releases
  • 2019
December 23, 2019
Press releases
Sanofi commences tender offer for acquisition of Synthorx, Inc.
December 10, 2019
Press releases
Sanofi : Positive results presented from pivotal Phase 3 trial of sutimlimab in people with cold agglutinin disease
December 10, 2019
Press releases
Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
December 9, 2019
Press releases
Sanofi : Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion
December 9, 2019
Press releases
Sanofi CEO unveils new strategy to drive innovation and growth
November 4, 2019
Press releases
Sanofi : FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older
November 4, 2019
Press releases
Sanofi : Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes
October 31, 2019
Press releases
Sanofi announces settlement agreement related to Contingent Value Rights (CVRs) Litigation
October 31, 2019
Press releases
Sanofi Q3 well on track
October 29, 2019
Press releases
Sanofi : Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis
October 15, 2019
Press releases
Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing
October 1, 2019
Press releases
Sanofi : Availability of the Pre-quarterly Results Communication
September 30, 2019
Press releases
Sanofi : New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer
September 20, 2019
Press releases
Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis  
September 16, 2019
Press releases
Sanofi and Abbott partner to integrate glucose sensing and insulin delivery technologies to help change the way diabetes is managed
August 28, 2019
Press releases
Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9
August 6, 2019
Press releases
Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
August 6, 2019
Press releases
Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis
July 29, 2019
Press releases
Sanofi : Online Availability of Sanofi Group’s Half-Year Financial Report for 2019
July 29, 2019
Press releases
Sanofi delivered solid growth in Q2 2019
July 26, 2019
Press releases
Sanofi :  Sanofi provides update on ZynquistaTM (sotagliflozin) type 2 diabetes Phase 3 program and collaboration with Lexicon
July 26, 2019
Press releases
Sanofi : Information on the departure conditions of Olivier Brandicourt, Chief Executive Officer
July 23, 2019
Press releases
Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu® in Flu Care
July 10, 2019
Press releases
Sanofi : FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma
July 2, 2019
Press releases
Sanofi : Availability of the Pre-quarterly Results Communication
July 1, 2019
Press releases
Sanofi : Libtayo® (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union
June 28, 2019
Press releases
Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents
June 27, 2019
Press releases
Sanofi : FDA to review MenQuadfi, a meningococcal vaccine candidate
June 26, 2019
Press releases
Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis
June 21, 2019
Press releases
Sanofi and Regeneron announce positive topline Phase 2 results for IL-33 antibody in asthma
June 18, 2019
Press releases
Sanofi and Google to develop new healthcare Innovation Lab
June 9, 2019
Press releases
Soliqua® Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments
June 7, 2019
Press releases
Paul Hudson to succeed Olivier Brandicourt as Chief Executive Officer
June 2, 2019
Press releases
Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma
May 7, 2019
Press releases
Sanofi : Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
April 30, 2019
Press releases
Sanofi: Annual General Meeting of April 30, 2019
April 27, 2019
Press releases
Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization
April 26, 2019
Press releases
Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER
April 26, 2019
Press releases
ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes
April 26, 2019
Press releases
CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma
April 8, 2019
Press releases
Sanofi: Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance
April 1, 2019
Press releases
Sanofi: Availability of the Pre-quarterly Results Communication
March 22, 2019
Press releases
Sanofi: FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin)
March 15, 2019
Press releases
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
March 13, 2019
Press releases
Sanofi successfully prices EUR 2 billion of bond issues
March 8, 2019
Press releases
Sanofi: Filing of the 2018 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report
March 8, 2019
Press releases
Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps
March 1, 2019
Press releases
Sanofi : CHMP recommends ZynquistaTM (sotagliflozin) for the treatment of adults with type 1 diabetes
March 1, 2019
Press releases
Sanofi: CHMP recommends approval of Dupixent® (dupilumab) for asthma indication
February 25, 2019
Press releases
Sanofi : Sanofi and Regeneron strongly disagree with verdict upholding three of five Amgen U.S. patent claims relating to PCSK9 antibodies
February 25, 2019
Press releases
Sanofi: Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
February 12, 2019
Press releases
Sanofi appoints Ameet Nathwani Chief Digital Officer
February 7, 2019
Press releases
Sanofi delivers 2018 business EPS growth of 5.1% at CER
February 6, 2019
Press releases
Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
February 6, 2019
Press releases
Sanofi's Board of Directors notes the resignation of Christian Mulliez and co-opts Christophe Babule as Director
February 5, 2019
Press releases
Sanofi : Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
February 4, 2019
Press releases
Sanofi : CHMP recommends approval of Praluent® (alirocumab) to reduce cardiovascular risk in people with established atherosclerotic cardiovascular disease
January 30, 2019
Press releases
Sanofi: Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo
January 18, 2019
Press releases
Sanofi: FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes
January 11, 2019
Press releases
Sanofi: Availability of the Pre-quarterly Results Communication
January 9, 2019
Press releases
New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi® (caplacizumab) for rare blood clotting disorder
January 7, 2019
Press releases
Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
Sanofi

    Follow us

  • Contact
  • Legal notice
  • Privacy & Data Protection
  • Cookies policy
  • Corporate code of ethics
  • Our publications
  • Sitemap
  • Our websites
  • Accessibility: partial compliance

© Sanofi 2004-2022 - All rights reserved

You are about to leave sanofi.com

If you wish to continue to this external website, click Proceed.

It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.

PROCEED